Article Text

PDF
Is it time to re-assess the role of gliclazide? Targeting insulin resistance in type 2 diabetes patients suboptimally controlled with insulin
  1. N Brown
  1. Correspondence to:
 Dr N Brown
 Yardley Green Medical Centre, 73 Yardley Green Road, Birmingham B9 5PU, UK; Neil.Brown{at}EasternBirminghamPCT.nhs.uk

Abstract

Background: Adult patients with type 2 diabetes controlled with insulin frequently require the addition of insulin sensitising drugs such as metformin and sometimes glitazones to achieve optimum glycaemic control. Five of a group of eight people with suboptimal diabetes control who were treated by the introduction of gliclazide are reported on. Three patients were excluded. One with type 1 diabetes and two others who had dietary or other therapeutic interventions coinciding with re-introduction gliclazide. Does the re-introduction of gliclazide effect a clinically significant improvement in glycaemic control in type 2 diabetes patients with suboptimal control taking combinations of short and long acting insulin plus metformin?

Method: Five adult patients with type 2 diabetes with suboptimal control using combinations of short and long acting insulin plus metformin who were adherent to their dietary regimen were treated by the addition of gliclazide at different doses. Two of the patients were taking pioglitazone in addition to metformin and insulin. Their glycaemic control was monitored over the following six months.

Results: All five showed significant improvement in glycaemic control after three months. Mean reduction in HbA1c was 1.4% (range 0.9% to 2.5%). Six months after the introduction of gliclazide four patients had HbA1c below base line figure and in two patients clinically significant improvement had been maintained.

Conclusion: A double blind randomised placebo control study is necessary to evaluate a possible role for gliclazide in type 2 diabetes patients who have suboptimal glycaemic control using combinations of short and long acting insulin plus metformin.

  • type 2 diabetes
  • gliclazide

Statistics from Altmetric.com

Footnotes

  • * HbA1c measurements were carried out using a DCCT aligned method (normal range 4.3% to 6.5%) at George Eliot Hospital, Nuneaton, UK using high performance liquid chromatography method. The machine type was HA 8160 supplied by A Menarini Diagnostics.

  • Funding: the study was not sponsored. The observations were made during routine diabetic surveillance. The measurements of HbA1c were carried out at the George Eliot Hospital, Nuneaton using a DCCT aligned method as part of the routine assessment and management of the diabetic care of the people involved.

  • Conflicts of interest: none.

  • Ethical approval was not sought for this retrospective observational study because gliclazide is widely used in the management of patients with type 2 diabetes controlled with insulin. The variation from standard practice was to re-introduce gliclazide only when suboptimal control was achieved with insulin and maximum tolerated metformin.

    Consent: verbal consent was obtained from patients before re-introduction of gliclazide: written consent for publication was obtained subsequently.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.